We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Stay Neutral on TDOC Stock for Now
Read MoreHide Full Article
Key Takeaways
Teladoc Health is expanding through chronic care, international growth and its upcoming Teladoc One platform.
BetterHelp revenues fell 11.6%, while its adjusted EBITDA margin dropped to 0.2% in Q2 2026.
TDOC remains unprofitable and faces intense virtual-care competition that could pressure growth and pricing.
Teladoc Health, Inc. (TDOC - Free Report) is well-positioned for growth, supported by broad clinical capabilities, connected-care innovation, strategic acquisitions and an expanding international presence. Over the past six months, TDOC stock has gained 22.7% compared with the industry’s 5.9% growth.
With a market capitalization of approximately $1.1 billion, TDOC operates through two main segments — Integrated Care and BetterHelp. From a valuation standpoint, the stock appears to be trading at a discount. The company has a forward Price-to-Sales ratio of 0.47X, which is below the industry average of 0.53X.
Courtesy of solid prospects, TDOC currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for TDOC Stand?
The Zacks Consensus Estimate for Teladoc Health’s 2026 loss is pegged at 89 cents per share, suggesting a 21.9% year-over-year increase. In the past 30 days, it has witnessed three upward estimate revisions against one in the opposite direction. The consensus estimate for revenues is pegged at $2.4 billion for 2026.
TDOC beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 11.4%.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health’s growth prospects are increasingly tied to deeper penetration of its Integrated Care platform, particularly chronic care. Chronic Care Program enrollment reached 1.27 million at the end of June 2026, up 14% year over year, helped by greater adoption of multi-condition bundles. In the second quarter of 2026, Integrated Care revenues increased 0.7% year over year to $394.3 million, with hybrid care revenues rising 30%.
International expansion and broader distribution channels provide another avenue for growth. International revenues increased 7% year over year to $119.6 million in the second quarter of 2026. The company expects international revenues to grow in the high-single digit on an organic constant-currency basis in 2026. The Telecare acquisition also contributed to Integrated Care’s revenue growth in the second quarter, supporting Teladoc Health’s international expansion strategy. Additionally, partnerships with platforms such as Walmart are extending Teladoc Health’s reach beyond traditional employer and health-plan channels, giving consumers easier access to virtual urgent care, dermatology and nutrition services.
A major part of Teladoc Health’s next phase is Teladoc One, a more unified care model that combines multidisciplinary care teams, connected health data and always-on AI support. The platform is designed to coordinate care across chronic conditions, mental health, primary care and other needs rather than treating each condition separately. Programs are scheduled to begin with select clients in September 2026, followed by broader availability in January 2027.
Meanwhile, BetterHelp is undergoing a strategic shift toward insurance-based, in-network services, which could create a more durable growth model over time. The company has contracted for more than 150 million in-network lives and credentialed more than 8,000 mental-health professionals. TDOC is also investing in provider recruitment, network capacity, platform efficiency and targeted marketing to support further growth in its insurance-based business.
Risks for TDOC Stock
There are some factors, however, that investors should keep a careful eye on.
BetterHelp remains a key concern for Teladoc Health as weakness in the cash-pay mental health business continues to weigh on results. BetterHelp revenues declined 11.6% year over year to $212.6 million in the second quarter of 2026, while its adjusted EBITDA margin fell to just 0.2%.
Teladoc Health faces intense competition in the virtual care market, which could pressure pricing and growth. The company also remains unprofitable, reporting an accumulated deficit of $16.5 billion as of June 30, 2026, largely due to substantial investments in growth initiatives and technology.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.99 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed two upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
View the Zacks #1 Rank List
Image: Shutterstock
Here's Why Investors Should Stay Neutral on TDOC Stock for Now
Key Takeaways
Teladoc Health, Inc. (TDOC - Free Report) is well-positioned for growth, supported by broad clinical capabilities, connected-care innovation, strategic acquisitions and an expanding international presence. Over the past six months, TDOC stock has gained 22.7% compared with the industry’s 5.9% growth.
With a market capitalization of approximately $1.1 billion, TDOC operates through two main segments — Integrated Care and BetterHelp. From a valuation standpoint, the stock appears to be trading at a discount. The company has a forward Price-to-Sales ratio of 0.47X, which is below the industry average of 0.53X.
Courtesy of solid prospects, TDOC currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for TDOC Stand?
The Zacks Consensus Estimate for Teladoc Health’s 2026 loss is pegged at 89 cents per share, suggesting a 21.9% year-over-year increase. In the past 30 days, it has witnessed three upward estimate revisions against one in the opposite direction. The consensus estimate for revenues is pegged at $2.4 billion for 2026.
TDOC beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 11.4%.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health, Inc. price-consensus-eps-surprise-chart | Teladoc Health, Inc. Quote
TDOC’s Growth Drivers
Teladoc Health’s growth prospects are increasingly tied to deeper penetration of its Integrated Care platform, particularly chronic care. Chronic Care Program enrollment reached 1.27 million at the end of June 2026, up 14% year over year, helped by greater adoption of multi-condition bundles. In the second quarter of 2026, Integrated Care revenues increased 0.7% year over year to $394.3 million, with hybrid care revenues rising 30%.
International expansion and broader distribution channels provide another avenue for growth. International revenues increased 7% year over year to $119.6 million in the second quarter of 2026. The company expects international revenues to grow in the high-single digit on an organic constant-currency basis in 2026. The Telecare acquisition also contributed to Integrated Care’s revenue growth in the second quarter, supporting Teladoc Health’s international expansion strategy. Additionally, partnerships with platforms such as Walmart are extending Teladoc Health’s reach beyond traditional employer and health-plan channels, giving consumers easier access to virtual urgent care, dermatology and nutrition services.
A major part of Teladoc Health’s next phase is Teladoc One, a more unified care model that combines multidisciplinary care teams, connected health data and always-on AI support. The platform is designed to coordinate care across chronic conditions, mental health, primary care and other needs rather than treating each condition separately. Programs are scheduled to begin with select clients in September 2026, followed by broader availability in January 2027.
Meanwhile, BetterHelp is undergoing a strategic shift toward insurance-based, in-network services, which could create a more durable growth model over time. The company has contracted for more than 150 million in-network lives and credentialed more than 8,000 mental-health professionals. TDOC is also investing in provider recruitment, network capacity, platform efficiency and targeted marketing to support further growth in its insurance-based business.
Risks for TDOC Stock
There are some factors, however, that investors should keep a careful eye on.
BetterHelp remains a key concern for Teladoc Health as weakness in the cash-pay mental health business continues to weigh on results. BetterHelp revenues declined 11.6% year over year to $212.6 million in the second quarter of 2026, while its adjusted EBITDA margin fell to just 0.2%.
Teladoc Health faces intense competition in the virtual care market, which could pressure pricing and growth. The company also remains unprofitable, reporting an accumulated deficit of $16.5 billion as of June 30, 2026, largely due to substantial investments in growth initiatives and technology.
Stocks to Consider
Some better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.99 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed two upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.